COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug–Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts

Category Primary study
JournalDermatology and Therapy
Year 2021
This article has no abstract
Epistemonikos ID: e3fb26e555b136c09d3f2108d52c6de106f70f2c
First added on: Feb 13, 2025